The stock has a 36-month beta value of -2.98. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PHVS is 18.95M, and at present, short sellers hold a 0.66% of that float. On August 14, 2024, the average trading volume of PHVS was 58.39K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
PHVS) stock’s latest price update
Pharvaris NV (NASDAQ: PHVS)’s stock price has soared by 16.21 in relation to previous closing price of 15.73. Nevertheless, the company has seen a gain of 5.91% in its stock price over the last five trading days. globenewswire.com reported 2024-06-11 that ZUG, Switzerland, June 11, 2024 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the annual general meeting of shareholders will take place on Friday, June 28, 2024, at 15:00 CEST (9:00 a.m. EDT).
PHVS’s Market Performance
Pharvaris NV (PHVS) has seen a 5.91% rise in stock performance for the week, with a 2.35% gain in the past month and a -13.65% plunge in the past quarter. The volatility ratio for the week is 8.65%, and the volatility levels for the past 30 days are at 6.58% for PHVS. The simple moving average for the past 20 days is 5.27% for PHVS’s stock, with a -16.45% simple moving average for the past 200 days.
Analysts’ Opinion of PHVS
Many brokerage firms have already submitted their reports for PHVS stocks, with Wedbush repeating the rating for PHVS by listing it as a “Outperform.” The predicted price for PHVS in the upcoming period, according to Wedbush is $27 based on the research report published on September 25, 2023 of the previous year 2023.
Morgan Stanley, on the other hand, stated in their research note that they expect to see PHVS reach a price target of $34, previously predicting the price at $10. The rating they have provided for PHVS stocks is “Overweight” according to the report published on August 15th, 2023.
Bryan Garnier gave a rating of “Buy” to PHVS, setting the target price at $16 in the report published on October 05th of the previous year.
PHVS Trading at 3.74% from the 50-Day Moving Average
After a stumble in the market that brought PHVS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.61% of loss for the given period.
Volatility was left at 6.58%, however, over the last 30 days, the volatility rate increased by 8.65%, as shares sank -1.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.59% lower at present.
During the last 5 trading sessions, PHVS rose by +5.91%, which changed the moving average for the period of 200-days by -2.51% in comparison to the 20-day moving average, which settled at $17.35. In addition, Pharvaris NV saw -34.83% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PHVS starting from JOAN MARIE SCHMIDT, who proposed sale 1,201 shares at the price of $19.15 back on Aug 13 ’24. After this action, JOAN MARIE SCHMIDT now owns shares of Pharvaris NV, valued at $22,994 using the latest closing price.
Stock Fundamentals for PHVS
The total capital return value is set at -0.24. Equity return is now at value -43.59, with -40.51 for asset returns.
Based on Pharvaris NV (PHVS), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -476.14. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -3235.97.
Currently, EBITDA for the company is -94.67 million with net debt to EBITDA at 4.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 20.53.
Conclusion
To sum up, Pharvaris NV (PHVS) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
